Sirio introduces GummiBiotic line for strengthening immunity, enhancing digestive health, and managing weight

The company is using CPHI Milan to showcase the new range, which features three products: GummiBiotics Defense, GummiBiotics IBS Ease, and GummiBiotics Lean. The products are formulated with ingredients like EpiCor postbiotic and DE111 probiotic.

“At Sirio we are very proud of our R&D capabilities, where we continue to invest a significant portion of our earnings: our technical and formulation teams account for 13% of our total employee base, something unique for a CDMO,” said Sara Lesina, General Manager Sirio Europe & Americas.

“We are constantly working with our customers and our experts to not just follow the trends but make first-in-class new products that will drive sales in new areas – and each one of these concepts is a true first for nutraceutical brands. So, we are incredibly excited to launch the new GummiBiotics range as it continues building on our partnerships with some of the best ingredient suppliers and it combines the benefits of science-backed biotics with gummies that are truly delicious.”

A booming market​

The biotic supplement segment already accounts for a quarter of all supplements sold, said Sirio in a press release.

Probiotics are still the dominating subcategory under biotics, a spokesperson for the company told us. For EU market, the probiotic supplement market has the market size of $1.7 billion in 2023, with a CAGR of 7% from 2021-2024, according to Euromonitor 2024.

The global gummy market is also soaring, with an average of 14% CAGR since 2020. From 2020 to 2025, the European gummy market is forecast to grow over 50% from around US$ 240 million in 2022 to nearly US$ 385 million in 2025, said the spokesperson.